Teladoc Health Reports Second-Quarter 2021 Results, Raises Full-Year Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Teladoc (TDOC) Falls 6% on Growing Losses and Weak Guidance to Prompt a Downgrade to 'Hold' at Deutsche Bank
July 28, 2021 10:01 AM EDTShares of Teladoc Health (NYSE: TDOC) are down more than 6% in todays trading session after the company presented disappointing Q2 results.
The company reported a loss of $0.86 per share while the surveyed analysts were expecting a loss of just $0.53 per share. Losses have more than doubled compared to $0.34 a year ago. Revenue grew 109% year-over-year to $503 million.
Teladoc Health delivered a strong second quarter, marked by exciting new client wins, product launches, and tremendous progress on our quest to be the category-defining provider of whole person virtual care, said Jason Gorevic, chief executive... More
Teladoc (TDOC) PT Lowered to $185 at Cantor Fitzgerald
July 28, 2021 6:46 AM EDTCantor Fitzgerald analyst Steven Halper lowered the price target on Teladoc (NYSE: TDOC) to $185.00 (from $210.00) while maintaining a Neutral rating.
The analyst commented, "We reiterate our Neutral rating on TDOC shares and lower our price target to $185 from $210. After the market close on Tuesday, July 27, TDOC reported 2Q21 results. Revenue and... More
Teladoc (TDOC) Q2 Revenue Tops Consensus, Offers Guidance
July 27, 2021 4:13 PM EDTTeladoc (NYSE: TDOC) reported Q2 EPS of ($0.86), may not compare to the analyst estimate of ($0.56). Revenue for the quarter came in at $503 million versus the consensus estimate of $500.7 million.
GUIDANCE:
Teladoc sees Q3 2021 EPS of ($0.78)-($0.68), versus the consensus of... More
